Antifungal drugs: New insights in research & development
The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance...
Gespeichert in:
Veröffentlicht in: | Pharmacology & therapeutics (Oxford) 2019-03, Vol.195, p.21-38 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 38 |
---|---|
container_issue | |
container_start_page | 21 |
container_title | Pharmacology & therapeutics (Oxford) |
container_volume | 195 |
creator | Nicola, André Moraes Albuquerque, Patrícia Paes, Hugo Costa Fernandes, Larissa Costa, Fabricio F. Kioshima, Erika Seki Abadio, Ana Karina Rodrigues Bocca, Anamélia Lorenzetti Felipe, Maria Sueli |
description | The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides. |
doi_str_mv | 10.1016/j.pharmthera.2018.10.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2138636087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016372581830192X</els_id><sourcerecordid>2138636087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</originalsourceid><addsrcrecordid>eNqFkEtPwzAMgCMEYmPwF1BPiEtLHm2TchsTL2mCC0jcoix11kx9kbRD_HsyjceRky37sy1_CEUEJwST_GqT9JVyzVCBUwnFRIRygrE4QFMieBEH5u0QTUNgMaeZmKAT7zcY4zTF9BhNGGYpp4ROkZi3gzVju1Z1VLpx7a-jJ_iIbOvtuhp8SCIHHpTTVXQRlbCFuusbaIdTdGRU7eHsO87Q693ty-IhXj7fPy7my1gzng4xZUUKOKMGlwXVaV5oohglucmMIJSH1GC64kSRrKQFKQk2kLHM5MAoT2HFZuhyv7d33fsIfpCN9RrqWrXQjV5SwkTOcix4QMUe1a7z3oGRvbONcp-SYLnzJjfyz5vcedt1grcwev59ZVw1UP4O_ogKwM0egPDr1oKTXltoNZTWgR5k2dn_r3wBvAuCBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138636087</pqid></control><display><type>article</type><title>Antifungal drugs: New insights in research & development</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</creator><creatorcontrib>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</creatorcontrib><description>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2018.10.008</identifier><identifier>PMID: 30347212</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Antibodies, Monoclonal - therapeutic use ; Antifungal Agents - therapeutic use ; Antifungal immunotherapy ; Biological Products - therapeutic use ; Drug Development ; Drug discovery and development ; Drug targets ; Essential genes ; Humans ; Immunotherapy ; Mycoses - therapy ; Rational drug design ; Systemic mycoses ; Vaccines - therapeutic use</subject><ispartof>Pharmacology & therapeutics (Oxford), 2019-03, Vol.195, p.21-38</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</citedby><cites>FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2018.10.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30347212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nicola, André Moraes</creatorcontrib><creatorcontrib>Albuquerque, Patrícia</creatorcontrib><creatorcontrib>Paes, Hugo Costa</creatorcontrib><creatorcontrib>Fernandes, Larissa</creatorcontrib><creatorcontrib>Costa, Fabricio F.</creatorcontrib><creatorcontrib>Kioshima, Erika Seki</creatorcontrib><creatorcontrib>Abadio, Ana Karina Rodrigues</creatorcontrib><creatorcontrib>Bocca, Anamélia Lorenzetti</creatorcontrib><creatorcontrib>Felipe, Maria Sueli</creatorcontrib><title>Antifungal drugs: New insights in research & development</title><title>Pharmacology & therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Antifungal immunotherapy</subject><subject>Biological Products - therapeutic use</subject><subject>Drug Development</subject><subject>Drug discovery and development</subject><subject>Drug targets</subject><subject>Essential genes</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Mycoses - therapy</subject><subject>Rational drug design</subject><subject>Systemic mycoses</subject><subject>Vaccines - therapeutic use</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtPwzAMgCMEYmPwF1BPiEtLHm2TchsTL2mCC0jcoix11kx9kbRD_HsyjceRky37sy1_CEUEJwST_GqT9JVyzVCBUwnFRIRygrE4QFMieBEH5u0QTUNgMaeZmKAT7zcY4zTF9BhNGGYpp4ROkZi3gzVju1Z1VLpx7a-jJ_iIbOvtuhp8SCIHHpTTVXQRlbCFuusbaIdTdGRU7eHsO87Q693ty-IhXj7fPy7my1gzng4xZUUKOKMGlwXVaV5oohglucmMIJSH1GC64kSRrKQFKQk2kLHM5MAoT2HFZuhyv7d33fsIfpCN9RrqWrXQjV5SwkTOcix4QMUe1a7z3oGRvbONcp-SYLnzJjfyz5vcedt1grcwev59ZVw1UP4O_ogKwM0egPDr1oKTXltoNZTWgR5k2dn_r3wBvAuCBQ</recordid><startdate>201903</startdate><enddate>201903</enddate><creator>Nicola, André Moraes</creator><creator>Albuquerque, Patrícia</creator><creator>Paes, Hugo Costa</creator><creator>Fernandes, Larissa</creator><creator>Costa, Fabricio F.</creator><creator>Kioshima, Erika Seki</creator><creator>Abadio, Ana Karina Rodrigues</creator><creator>Bocca, Anamélia Lorenzetti</creator><creator>Felipe, Maria Sueli</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201903</creationdate><title>Antifungal drugs: New insights in research & development</title><author>Nicola, André Moraes ; Albuquerque, Patrícia ; Paes, Hugo Costa ; Fernandes, Larissa ; Costa, Fabricio F. ; Kioshima, Erika Seki ; Abadio, Ana Karina Rodrigues ; Bocca, Anamélia Lorenzetti ; Felipe, Maria Sueli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-2394e052f0d92c469c1a3216f5f8127321f02b71a15d291d10fe535f6e3274eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Antifungal immunotherapy</topic><topic>Biological Products - therapeutic use</topic><topic>Drug Development</topic><topic>Drug discovery and development</topic><topic>Drug targets</topic><topic>Essential genes</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Mycoses - therapy</topic><topic>Rational drug design</topic><topic>Systemic mycoses</topic><topic>Vaccines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nicola, André Moraes</creatorcontrib><creatorcontrib>Albuquerque, Patrícia</creatorcontrib><creatorcontrib>Paes, Hugo Costa</creatorcontrib><creatorcontrib>Fernandes, Larissa</creatorcontrib><creatorcontrib>Costa, Fabricio F.</creatorcontrib><creatorcontrib>Kioshima, Erika Seki</creatorcontrib><creatorcontrib>Abadio, Ana Karina Rodrigues</creatorcontrib><creatorcontrib>Bocca, Anamélia Lorenzetti</creatorcontrib><creatorcontrib>Felipe, Maria Sueli</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology & therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nicola, André Moraes</au><au>Albuquerque, Patrícia</au><au>Paes, Hugo Costa</au><au>Fernandes, Larissa</au><au>Costa, Fabricio F.</au><au>Kioshima, Erika Seki</au><au>Abadio, Ana Karina Rodrigues</au><au>Bocca, Anamélia Lorenzetti</au><au>Felipe, Maria Sueli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antifungal drugs: New insights in research & development</atitle><jtitle>Pharmacology & therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2019-03</date><risdate>2019</risdate><volume>195</volume><spage>21</spage><epage>38</epage><pages>21-38</pages><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>30347212</pmid><doi>10.1016/j.pharmthera.2018.10.008</doi><tpages>18</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-7258 |
ispartof | Pharmacology & therapeutics (Oxford), 2019-03, Vol.195, p.21-38 |
issn | 0163-7258 1879-016X |
language | eng |
recordid | cdi_proquest_miscellaneous_2138636087 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Antibodies, Monoclonal - therapeutic use Antifungal Agents - therapeutic use Antifungal immunotherapy Biological Products - therapeutic use Drug Development Drug discovery and development Drug targets Essential genes Humans Immunotherapy Mycoses - therapy Rational drug design Systemic mycoses Vaccines - therapeutic use |
title | Antifungal drugs: New insights in research & development |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A36%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antifungal%20drugs:%20New%20insights%20in%20research%20&%20development&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Nicola,%20Andr%C3%A9%20Moraes&rft.date=2019-03&rft.volume=195&rft.spage=21&rft.epage=38&rft.pages=21-38&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2018.10.008&rft_dat=%3Cproquest_cross%3E2138636087%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138636087&rft_id=info:pmid/30347212&rft_els_id=S016372581830192X&rfr_iscdi=true |